New drug combo may keep leukemia at bay after transplant

NCT ID NCT03286530

First seen Mar 31, 2026 · Last updated May 17, 2026 · Updated 5 times

Summary

This study tests whether the drug ruxolitinib can lower the chance of leukemia returning after a stem cell transplant in older adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Participants take ruxolitinib as a maintenance therapy after transplant. The goal is to improve survival without causing severe graft-versus-host disease (GVHD).

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02115, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02115, United States

  • Medical College of Wisconsin

    Wauwatosa, Wisconsin, 53226, United States

  • The Ohio State University

    Columbus, Ohio, 43210, United States

  • Vanderbilt University

    Nashville, Tennessee, 37235, United States

  • Washington University

    St Louis, Missouri, 63130, United States

Conditions

Explore the condition pages connected to this study.